To conclude, ITZ-siRNAVEGF-NPs could reduce VEGF and CD31 expression through the synergistic effect of ITZ and VEGF siRNA and inhibited growth and angiogenesis of breast cancer in vivo. This evidence concerns the gene PECAM1 and breast cancer.